NO742946L - - Google Patents

Info

Publication number
NO742946L
NO742946L NO742946A NO742946A NO742946L NO 742946 L NO742946 L NO 742946L NO 742946 A NO742946 A NO 742946A NO 742946 A NO742946 A NO 742946A NO 742946 L NO742946 L NO 742946L
Authority
NO
Norway
Prior art keywords
acid
formula
acid addition
addition salts
residue
Prior art date
Application number
NO742946A
Other languages
Norwegian (no)
Inventor
A Mentrup
K Schromm
E O Renth
W Traunecker
Original Assignee
Boehringer Sohn Ingelheim
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Sohn Ingelheim filed Critical Boehringer Sohn Ingelheim
Publication of NO742946L publication Critical patent/NO742946L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00Preparation of carboxylic acid esters
    • C07C67/08Preparation of carboxylic acid esters by reacting carboxylic acids or symmetrical anhydrides with the hydroxy or O-metal group of organic compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/02Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
    • C07C69/22Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety
    • C07C69/24Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety esterified with monohydroxylic compounds
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Description

"Analogifremgangsmåte £or freraotilling av 1-(ra-acylokoyf©nyl) -1 -hydroksy-2-BT-alIcylamino-. "Analogous method for the preparation of 1-(ra-acyloxyl)-1-hydroxy-2-BT-alkylamino-.

:atener." :Athens."

Danne oppfinnelse angår cn analogifremgangsmåte for framatilling av l-(ra-acyloksy£enyl)°l-hydrokoy-2HSf-alkylamino*-etanQr med den This invention relates to an analogous process for the preparation of 1-(α-acyloxy£enyl)°1-hydroquin-2HSf-alkylamino*-ethaneQr with the

. generelle formelt . general formal

hvor R betyr en alkylrost med 3 til 19 karbonatomer, og &2betyr metyl eller etyl, og syreaddlsjonssaltar derav. where R means an alkyl group with 3 to 19 carbon atoms, and &2 means methyl or ethyl, and acid addition salts thereof.

Forbindelsene med formel I har et asymmetrisk karbonatora og kan derfor foreligge i form av raceraater eller i form av optisk aktive forbindelser. The compounds of formula I have an asymmetric carbonator and can therefore exist in the form of racemic radicals or in the form of optically active compounds.

De nye forbindelser fremstilles i henhold til oppfinnelsen ved re-duksjon av tilsvarende acetofenonderivater med formelent The new compounds are prepared in accordance with the invention by reduction of corresponding acetophenone derivatives with formalin

hvor R. og or som ovanfor angitt, og betyr hydrogen oller en eventuelt substituert benzylrest. Bensylresten kan f.eks. være substituert med alkyl--ellar alkoksygrupper eller et halogenatora, særlig et kloratom. Redaksjonen forståa ved katalytisk hydrogenering atad kjønto hydrogonaringskatalyoatorer, oom f.oke. Pd, Pt, Mi eller mad komplokss metallhydrider ned liten reduksjonskraft, som f.oko. natriuraborhydrid. Hvis reoton £1^^©tyr en bensylrest, fjernes den samtidig foycirogonolytiok vod don katalytiske hydrogen-er ing. Hvis roduksj 0:10:1 av kotogruppan foretas mod komplekse metallhydrider, avopaltaDbenzylgruppen dereftor ved katalytisk hydrogenering. 1 De utgangsforbindelosr rcsd den generell©formal II som anvendes ved f r omgang ømå ten, kasi fremstilles ved aeylering av m-hydroksy-acetofenoner med formalen3 hvor R2 og R3har don ovanfor angitte betydning, med et syreklorid med formalens where R. and or as indicated above, and means hydrogen or an optionally substituted benzyl residue. The benzyl residue can e.g. be substituted with alkyl--ellar alkoxy groups or a halogenator, in particular a chlorine atom. The editors understand by catalytic hydrogenation atad kjønto hydrogenation catalysts, oom f.oke. Pd, Pt, Mi or mad komplox metal hydrides have little reducing power, as f.oko. sodium borohydride. If reoton £1^^©tyr a benzyl residue, it is simultaneously removed foycirogonolytiok vod don catalytic hydrogen-er ing. If the reduction 0:10:1 of the koto group is carried out against complex metal hydrides, the benzyl group is then removed by catalytic hydrogenation. 1 The starting compounds rcsd the general ©formal II which is used in the first method are prepared by the aylation of m-hydroxy-acetophenones with formalin3 where R2 and R3 have the meanings given above, with an acid chloride with formalin

hvor R^har den ovenfor angitte betydning, og eventuelt påfølgende where R^ has the meaning stated above, and possibly subsequent

selektiv hydrogenolyse av Itenzylgruppen. Racemater av forbindelser med formel Z spaltes eventuelt på vanlig måte i antipodene. selective hydrogenolysis of the Itenzyl group. Racemates of compounds of formula Z are optionally cleaved in the usual way in the antipodes.

De nye forbindelser med formel I er baser og kan på vanlig måte overføres til de fysiologisk forlikelige syreaddisjonssalter. The new compounds of formula I are bases and can be transferred in the usual way to the physiologically compatible acid addition salts.

Syrer som er egnet til saltdannalse, er f.eks. mineralsyrer såAcids that are suitable for salt formation are e.g. mineral acids so

som saltsyre, bromhydrogensyre, jodhydrogensyre, fluorhydrogensyre, svovelsyre, fosforsyre, salpetersyre eller organiske syrer så such as hydrochloric acid, hydrobromic acid, hydroiodic acid, hydrofluoric acid, sulfuric acid, phosphoric acid, nitric acid or organic acids such

som eddiksyre, propionsyra, smørsyre, kapronsyre, kaprinoyre, valeriansyre, oksalsyre, malonsyre, ravoyre, maleinsyre, fumarsyra, melkesyre, vinsyre, sitronsyre, benzo2syra, p-hydroksybansoesyre, p-aminobenzoesyre, ftalsyro, kanelsyre, salicylsyre, askorbinsyre, metansulfonsyra, etanfosfonsyre, 8-klorteofyllin eller lignende. such as acetic acid, propionic acid, butyric acid, caproic acid, capric acid, valerian acid, oxalic acid, malonic acid, ravoyre, maleic acid, fumaric acid, lactic acid, tartaric acid, citric acid, benzo2syra, p-hydroxybenzoic acid, p-aminobenzoic acid, phthalic acid, cinnamic acid, salicylic acid, ascorbic acid, methanesulfonic acid, ethanephosphonic acid , 8-chlorotheophylline or the like.

De nye forbindelser msd dan generelle formel I og deres syreaddi-sjoneaalter utmerker seg ved verdifulle terapeutisk© egenskaper. De egner særlig som aktive stoffer i hjerte- og kretsløpmidler, og kan derfor anvendes tii behandling av hjertesvikt eller krétsløps-1idelser. The new compounds of the general formula I and their acid addition agents are distinguished by valuable therapeutic properties. They are particularly suitable as active substances in heart and circulatory agents, and can therefore be used in the treatment of heart failure or circulatory disorders.

Forbindelsene med den generelle formel 1 og deree eyreaddis-jonsoal-ter kan anvendes enteralt eller parenfceralt. De anvendes i doser på 5 til 100 mg. Forbiii&alsene med formal I og deres syreaddisjonssalter kan også anvendoc samman med aktive stoffer av andre typer. The compounds of the general formula 1 and deree eyreaddisjonsoalter can be used enterally or parenterally. They are used in doses of 5 to 100 mg. The preparations with formal I and their acid addition salts can also be used together with active substances of other types.

Egnede galeniske tilbsrodelsasformer er f.eks. tabletter, kapslar, stikkpiller, oppløsninger, omulojoner aerosoler eller pulvere, og for fremstilling av disse kan man anvende de vanlige galeniske hjelpestoffer, beeremidlor, sprengmidler eller smØremidler eller stoffer.som.gir en depotvirkning. Fremstilling av slike galeniske tilberedelseaformsr foretan på vanlig måte efter kjente tilbered-elsesmetoder. Suitable galenic infusion forms are e.g. tablets, capsules, suppositories, solutions, omulions, aerosols or powders, and for the production of these you can use the usual galenic auxiliaries, beremidlor, explosives or lubricants or substances which give a depot effect. Preparation of such galenic preparation forms is carried out in the usual way according to known preparation methods.

De følgende eksempler skal t;jene til å illustrere oppfinnelsen ytter-ligere. The following examples shall serve to further illustrate the invention.

Eksempel 1Example 1

1-( m- stearvlokayfenvl) - l- hydroksv- 2HK- etglamino- etanhy<iroklorid.1-(m- stearvlocayphenvl)-1-hydroxy-2HK-ethglamino-ethanehy<irochloride.

a) ' m- Btearylokflv- torffi- atylaminoraTO . ■...a) ' m- Btearylokflv- torffi- atylaminoraTO . ■...

Ell en oppløi&nlhg av 53,0 g (0,25 mol) rh^yfiroksy-c^-etylamind- /. Ell a solution of 53.0 g (0.25 mol) of rhophyroxy-c^-ethylamine- /.

nrratofénon»Hci;i ICO es?, trifluoreddifcriyro oattoo dråpavis uiicloar ... ; omrøring vad 30 C 94,5 (j,(0,312. mol)', stoorylklorid.. perafter hol-. Cfåp ,roaksjonjjøfLandiAg&i i 5 minutter. vad•'. §DQC og : innrøres uten avkjøling, i .i: lit$r otylacatat.. DarVoi" okjor krystalliBasjon av forbindelsen., KrystP.IA^sis eveugoaog vfce&oo sæad etylacatat... '.Utbytta: .id8 'g, .8S,C;\; dat teoret:lr£c?L. Caoltepunkt: 195°c Xox»'»?: ciÆcryotailis.-.\rjj'osi-ffrai etandl). nrratofenone»Hci;i ICO es?, trifluoreddifcriyro oattoo dropwise uiicloar ... ; stirring vad 30 C 94.5 (j,(0.312. mol)', stoaryl chloride.. perafter hol-. Cfå,roaksjonjøfLandiAg&i for 5 minutes. vad•'. §DQC and : stir in without cooling, in .i: lit$r otylacatat.. DarVoi" okjor crystallization of the compound., KrystP.IA^sis eveugoaog vfce&oo sæad etylacatat... '.Yield: .id8 'g, .8S,C;\; dat theoret:lr£c?L. Caolte point: 195°c Xox»'»?: ciÆcryotailis.-.\rjj'osi-ffrai etandl).

-J) 1 - ( m- Btøarvlokev£e:.;.v::.) " 1- hvdrokPV-^. - IT^ tvlaTiino- QtanhvdgoIilpirid.-J) 1 - ( m- Btøarvlokev£e:.;.v::.) " 1- hvdrokPV-^. - IT^ tvlaTiino- QtanhvdgoIilpirid.

■<:.><...>" ■• . """ " ■'.. 72 g/(0,15 mol) s av ( lon i trinn h ej&olfviy*.£orbindeloé i i;44.iifcer'." /Atanol og 5"g 5&risT vÆiafiiiaa-^ 'åtaoejÆsæar cg 66C, ' Sfter' rtvfclwh'.:.>fc\hy3^ k&t&ly&ratoron, t>gisrøtanol^n -v" ^rafcillosæs." Yte/ c. ^rystailinoka ' raaltfuvni atr^es med acetonit^i"'. rtg-uvsugsG. utbyttes 69 g'.* 95,^. 1 r v £ot tøoreiirTo.' :.' Smaltepunkt: ■. 113°C £2c sfcanol). * ■ ■<:.><...>" ■• . """ " ■'.. 72 g/(0.15 mol) s of ( lon in step h ej&olfviy*.£orbindeloé i i;44.iifcer'. " /Atanol and 5"g 5&risT vÆiafiiiaa-^ 'åtaoejÆsæar cg 66C, ' Sfter' rtvfclwh'.:.>fc\hy3^ k&t&ly&ratoron, t>gisrøtanol^n -v" ^rafcillosæs." Yte/ c. ^rystailinoka ' raaltfuvni atr^es with acetonit^i"'. rtg-uvsugG. yield 69 g''.* 95,^. 1 r v £ot tøoreiirTo.' :.' Melting point: ■. 113°C £2c sfcanol). * ■

• Voi frpnigåhgBEiåtQn' L-' :?;'.^') cvonsfe-Aoncta'^?';r:o^3Sl;Erombtillos £r» ££lg-■■ Q^ido forbindelsens....' • Voi frpnigåhgBEiåtQn' L-' :?;'.^') cvonsfe-Aoncta'^?';r:o^3Sl;Erombtillos £r» ££lg-■■ Q^ido of the connection....'

??orbindelBer ;imed gQir-^.''. A te av Ir-y-irra^o Kidsinat ??orbindelBer ;imed gQir-^.'' A tea of Ir-y-irra^o Kidsinat

l-( m- stéarylbksvfanvlS -^V^vrlrokBy "2-H-^tvlayiino-otanhvdroklorrid.' ■ l-( m- stearylbksvfanvlS -^V^vrlrokBy "2-H-^tvlayiino-otanhvdrochlorride.' ■

A) m»stearvl6kov^ i>- W^ tylQaiÆO' <x! Ot6j:oaon»A) m»stearvl6kov^ i>- W^ tylQaiÆO' <x! Ot6j:oaon»

22 g m^ydroksy-o>* (53^tyl ^-benzyl-ani.:o) -acot<p>fenonhydroklorid 22 g m^hydroxy-o>* (53^thyl ^-benzyl-ani.:o)-acot<p>phenone hydrochloride

() ,.065$. mol) bppløoos'£ 157 ml 1 n natronlut, og under omrøring () ,.065$. mol) bppløoos'£ 157 ml 1 n caustic soda, and while stirring

vad 20 C /tilsettes dr&psvis.22 g (0,0725 mol) stoarylklprid. after'- 20 minutter .opptas.acylér{ngsproduktet;± eter, og derefter . at 20 C /add 22 g (0.0725 mol) stoaryl chloride dropwise. after'- 20 minutes, the acylation product; ± ether is taken up, and then .

rystes:dehiorganiske fase først rød 1 n.nafcrbnlut bg dereftér ..-med vann. Den tørrede ct.^rfaDo iimdc^osusYpg residuet hydrogen-aros^mad .390 .ml S6^-ig rr.Jtanol, soa inneholder den beregnede'vasng-de\hydrogenklorid, lø. a?, ;jalle^iua-kloi:;i.d "og 1 g kull under trykk vdd;60°C. bebenjsylorinc;;ia ar'avclutfcev.©£t<sr 5.minutter,* og hydro-gsneringen stander. ■ Katnlyoiitoron av<3t>.g;is.i.varm tilstand, og xxari^ Lt^ B^^ ^^ o^ Xl- y^^& a don ønskes forbindelse ved avkjøl- "" ing,.."' ilåter' *avsugtt5.nc,,.J;^' vrakes kry£iteI?.-'.%io ' ;oad' acotoriitril,: .■ ,. ■'' VK&yttø:- 22 -g" * -SO^ST.' riv det-"teoretisk?/. V-- -:' '. ftcii^sgnuftt-t 195°^ (ov<*,->2y8tåiXioesjca- -Crn etanol). shaken: dehiorganic phase first red 1 n.nafcrbnlut bg thenftér ..-with water. The dried ct.^rfaDo iimdc^osusYpg the residue hydrogen-aros^mad .390 .ml S6^-ig rr.Jtanol, soa contains the calculated'vasng-de\hydrogen chloride, Sat. a?, ;jalle^iua-kloi:;i.d "and 1 g of coal under pressure vdd;60°C. bebenjsylorinc;;ia ar'avclutfcev.©£t<sr 5.minutes,* and the hydrogenation stands. ■ Katnlyoiitoron of<3t>.g;is.i.hot state, and xxari^ Lt^ B^^ ^^ o^ Xl- y^^& a don desired connection by cooling- "" ing,.."' ilets' *avsugtt5.nc,,.J;^' wrecks kry£iteI?.-'.%io ' ;oad' acotoriitril,: .■ ,. ■'' VK&yttø:- 22 -g" * -SO^ST.' tear it-“theoretically?/. V-- -:' '. ftcii^sgnuftt-t 195°^ (ov<*,->2y8tåiXioesjca- -Crn ethanol).

■£) IM CT^ téarvlokoyforåy 7.) - -1 • -^T/jlrr glt sv-; * ::?- - atylamino - etanhvdrofclo. rid. ■£) IM CT^ téarvlokoyforåy 7.) - -1 • -^T/jlrr glt sv-; * ::?- - ethylamino - ethanehvdrofclo. ride.

....- ■<.>.<.>Vett .katalytiskhy&rogsivsring av 19 g t0,0395 mbl) av deia i,fcr.inn ... A ■ .^ifchplcjte^if.p^rbihdslscs i 400ral asafcahol i. ifcaryar - ov .0-/5-g pia^ista'*-olsréyd ved.nbrmaitsyklo oi?^0°C, feir «nr^' .g 96,5# av'det t,ep- . r^hÅakp^.Bv slu£t&ro£t-røfi tr^Ifeeov^t' 113°C (oakryétåll.invo-jon Ssr. ptaabl) "mslbg- ;fréfnbtilloo' l --.viyrylokoyffrjiH-./■.:.) • •i*;hydroks'y-2-S'~3t^l-. r^isrø^t^n-hydroklu:.*;!^. wja£$'teptuik^i' 139 v .(6v--?:**'/c.cfr.llic3ao'io3i ><:>rr.- icoprepanol).. ■' - V :"■ ■."*■» ■ » .... ■ ■ *..■'.. ....- ■<.>.<.>Vett .catalytic chy&rogsivsring of 19 g t0,0395 mbl) of deia i,fcr.inn ... A ■ .^ifchplcjte^if.p^rbihdslscs in 400ral asafcahol i. ifcaryar - ov .0-/5-g pia^ista'*-olsréyd at.nbrmaitsyklo oi?^0°C, feir «nr^' .g 96,5# of'it t,ep- . r^hÅakp^.Bv slu£t&ro£t-røfi tr^Ifeov^t' 113°C (oakryétåll.invo-jon Ssr. ptaabl) "mslbg- ;fréfnbtilloo' l --.viyrylokoyffrjiH-./■.:.) • •i*;hydroxys'y-2-S'~3t^l-. r^isrø^t^n-hydroclu:.* ;!^. wja£$'teptuik^i' 139 v .(6v--?:**'/c.cfr.llic3ao'io3i ><:>rr.- icoprepanol).. ■' - V :"■ ■."*■» ■ » .... ■ ■ *..■'..

1 - ( nt- rstéarvioksyf.- a^ ivli - fry^ roksv"?, v& • '^'^^ ivvgini^ etan- Sivdroklprici!..' 1 - ( nt- rstéarvioksyf.- a^ ivli - fry^ roksv"?, v& • '^'^^ ivvgini^ etan- Sivdroklprici!..'

30, 55 ' g; JtfO, 1 mol) in-hyÅroksy-tjr(K-eii^.- &-bangy1 -amino) -aeetpranon-åydrokibrid, oppløst i 250 ml 1 n nafcroalufc, omsattes ved rora--, temperatur'råsd 33";5 r; (-r>,ll mol) nte«:ty^kl.prid til m-stearyloksy-, c^(K^tyl-lff-bahByl-0'vli.-:o) -acetofenon-W^rofclorid. Bfter!20 minutter" f bre tas. utetr ing, og døn .esganisko. fase" rystes- med X »■ natroniu£ pg dorerte:-:'jrød vann. iJtiirfaaen tørres med hatriiAråsul-fat, og oppløsningBiaid^Glet avdeotilla^;ic.. Residuet' oppløses i G00, ml metanol,YiøytrF»*-'loaros msd. notøsioliok saltsyre og under-kastes .hydsrogénering oammøn mod Slanoy-Cii?il;el.. Hydrogeneringdn sK;.\ ox under, -trykfe. og .vad<:>-€0°C. Hydroconopptagelson svarer,il ; 2 ubl /ekvivalenter hyc!rsgen. 2fter frarjkiilelee av katalysatoren 30.55 g; JtfO, 1 mol) in-hydroxy-tjr(K-eii^.- &-bangy1 -amino)-aeetpranon-åhydrohybrid, dissolved in 250 ml of 1 n nafcroalufc, reacted at rora--, temperature'rawsd 33";5 r (-r>,ll mol) nte«:ty^kl.prid to m-stearyloxy-, c^(K^tyl-lff-bahByl-0'vli.-:o)-acetophenone-W^rofchloride. Bfter !20 minutes" f bre is taken. utetr ing, and die .esganisko. phase" is shaken- with X »■ natroniu£ pg dored:-:'jred water. The iJtiirfaa is dried with hatriiAråsul barrel, and solutionBiaid^Glet avdeotilla^;ic.. The residue' is dissolved in G00, ml of methanol,YiøtrF»*-' loaros msd. notösioliok hydrochloric acid and subjected to .hydrogenation ommøn mod Slanoy-Cii?il;el.. Hydrogeneringdn sK;.\ ox under, -pressfe. and .vad<:>-€0°C. Hydroconopptagelson answers,il ; 2 equivalents of hydrogen after removal of the catalyst

avdeetiileras metanolen i vakuum, og frr. residuet isoleres, den _ øswikede forbindelse...... ':• "; Ptbytté -35. g. 72.5?S r\v c?et teoretiske.... t»p.3ltapunkts 113°C (c.^ystailioaojon f.ira etanol).' the methanol is deethylated in vacuum, and the residue is isolated, the _ iswiked compound...... ':• "; Ptbytté -35. g. 72.5?S r\v c?et theoretical.... t»p.3ltapunkt 113°C (c.^ystalioaoion f.ira ethanol).'

Eksempel. 7 ■■■_.*.;'.<1>ti" . l^ rm- f n- nekBvlkarbonvlcc^ av) - fenvl ' 1 ~ l~ Iwc tr:okBv-- 2- l! ?-^ tvl-^ mlno-- etan--Iwdrbkiprid.^ Example. 7 ■■■_.*.;'.<1>ti" . l^ rm- f n- nekBvlkarbonvlcc^ av) - fenvl ' 1 ~ l~ Iwc tr:okBv-- 2- l! ?-^ tvl- ^ mlno-- etan--Iwdrbkiprid.^

<f>til.en oppløsning cv 2,*>.V g (0,Ol mol) iMn-hekoylkarbohyloksy) <f>to.a solution cv 2,*>.V g (0.Ol mol) iMn-hecoylcarbohyloxy)

.<o»^/^tylamino;yacetoisasi.;:.i.. ECl.i SO ml -jstanol tilføres under, jom-raring ved o :til .- écC 0.5 g natriunborliydrid. Sfter 5<:>:'minutter .<o»^/^tylamino;yacetoisasi.;:.i.. ECl.i SO ml -jstanol is added under, jom-raring at o :til .- écC 0.5 g of sodium boron liydride. Sfter 5<:>:'minutes

'iias&Btilles pH.på 5*_-5 ir.addik, og .nbfcasiolen."avdastiller3o i 'iias&Btilles pH.of 5*__-5 ir.addik, and .nbfcasiolen."abdastiller3o i

vÆuum; Residuet epplcH/iu i vann: og crjøros cvakt alkalisk vad til-- .. uatning av; arambhiuifi^yili/cilxyd. Den frigj:,rto base '.av • endof orhind-plncåft opptas, i etylac. tørros riir.d n^tariuiasulfat og inndavæas.Ss:ca residuet i etylfia.si.r^-. tttkryatalli:jor.:j.*u hydrokloridet av for-Mwdalson-iaed;'eterisk ^:'.\Uavre... Unyttes 2,7Å';'g rv det teoråtisk-i.-E^lfcepunkt"i 120°9 (o-■', .■..-..vTJtalliiao^on étylacetati). volume; The residue epplcH/iu in water: and crjøros cvak alkaline wad to-- .. uation of; arambhiuifi^yili/cilxyd. The released base '.of • endof orhind-plncåft is taken up, in ethylac. dry rose riir.d n^tariuiasulphate and indavæas.Ss:ca the residue in ethylfia.si.r^-. tttkryatalli:jor.:j.*u the hydrochloride of for-Mwdalson-iaed;'etheric ^:'.\Uavre... Unused 2.7Å';'g rv the theoretical-i.-E^lfcepoint"in 120° 9 (o-■', .■..-..vTJtalliiao^on ethylacetati).

• *. ■ ■ - . ■'..-*.■■' • *. ■ ■ - . ■'..-*.■■'

Claims (2)

1. Arialogifremgangsmåte for fremstilling av terapeutisk aktive l-(m-acyloksyfenyl) ' l-hydroksy-2-5!?-alkylaniino-etaner med den generelle formels 1. Arialogy process for the preparation of therapeutically active 1-(m-acyloxyphenyl)'' 1-hydroxy-2-5'-alkylaniino-ethanes of the general formula hvor betyr en alkylrest mad 3 til 19 karbonatomer, og R2 betyr metyl eller etyl, i form av racemater eller de rene optisk aktive former,- og syreaddisjonssalter derav, karakterisert ved at et acetofenon med formelen: where means an alkyl residue with 3 to 19 carbon atoms, and R2 means methyl or ethyl, in the form of racemates or the pure optically active forms, and acid addition salts thereof, characterized in that an acetophenone with the formula: hvor R, °9 R2 er som oven^or angitt, dg R betyr hydrogen eller en eventuelt substituert bensylrest, reduseres, en N-benzylrest som eventuelt er tilstede i reduksjonsproduktet, av-spaltes, racemater med formel I spaltes eventuelt i.de optiske antipoder, og/eller, primaert erholdte syreaddisjonssalter overføres til frie baser eller salter med andre syrer, eller primært erholdte, baser overføres til ønskede syreaddisjonssalter.where R, °9 R2 is as indicated above, dg R means hydrogen or an optionally substituted benzyl residue, is reduced, an N-benzyl residue which is possibly present in the reduction product is cleaved off, racemates of formula I are optionally split in the optical antipodes, and/or primarily obtained acid addition salts are transferred to free bases or salts with other acids, or primarily obtained bases are transferred to desired acid addition salts. 2. Fremgangsmåte som angitt i krav 1, karakterisert ved at det anvendes et utgangsmateriale med formel II hvor R^ betyr heptadekyl,•og R2 betyr etyl.2. Process as set forth in claim 1, characterized in that a starting material of formula II is used where R 1 means heptadecyl and R 2 means ethyl.
NO742946A 1973-08-18 1974-08-16 NO742946L (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19732341876 DE2341876A1 (en) 1973-08-18 1973-08-18 NEW 1- (M-ACYLOXYPHENYL) -1-HYDROXY-2-N-ALKYLAMINO-AETHANES, THEIR ACID-ADDITIONAL SALTS, THESE MEDICINAL PRODUCTS, AND THE PROCESS FOR THEIR PRODUCTION

Publications (1)

Publication Number Publication Date
NO742946L true NO742946L (en) 1975-03-17

Family

ID=5890134

Family Applications (1)

Application Number Title Priority Date Filing Date
NO742946A NO742946L (en) 1973-08-18 1974-08-16

Country Status (21)

Country Link
JP (1) JPS5049241A (en)
AT (1) AT340398B (en)
BE (1) BE818949A (en)
BG (1) BG24406A3 (en)
CH (1) CH603549A5 (en)
CS (1) CS167211B2 (en)
DD (1) DD115489A5 (en)
DE (1) DE2341876A1 (en)
DK (1) DK135942C (en)
ES (1) ES429178A1 (en)
FI (1) FI231674A (en)
FR (1) FR2240727B1 (en)
GB (1) GB1468079A (en)
HU (1) HU168905B (en)
IL (1) IL45482A0 (en)
NL (1) NL7410988A (en)
NO (1) NO742946L (en)
PL (1) PL95296B1 (en)
SE (1) SE7410492L (en)
SU (1) SU505351A3 (en)
ZA (1) ZA745267B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1492361A (en) * 1975-02-10 1977-11-16 Interx Research Corp Optically active m-acyloxy-alpha(methylamino)methyl)-benzyl alcohols the pharmaceutically acceptable acid addition salts thereof and synthesis of same
DE2933005C2 (en) * 1979-08-14 1983-01-13 Klinge Pharma GmbH, 8000 München 1- (3-Acyloxyphenyl) -2-aminoethanols, their acid addition salts, medicaments containing them, and processes for their preparation
CA3001981A1 (en) * 2014-10-14 2016-04-21 Sculpt B.V. Body sculpting

Also Published As

Publication number Publication date
FR2240727A1 (en) 1975-03-14
JPS5049241A (en) 1975-05-01
ATA651174A (en) 1977-04-15
CS167211B2 (en) 1976-04-29
AT340398B (en) 1977-12-12
FR2240727B1 (en) 1977-11-04
DK439774A (en) 1975-04-28
HU168905B (en) 1976-08-28
PL95296B1 (en) 1977-10-31
FI231674A (en) 1975-02-19
SU505351A3 (en) 1976-02-28
BE818949A (en) 1975-02-17
ZA745267B (en) 1976-04-28
AU7242874A (en) 1976-02-19
SE7410492L (en) 1975-02-19
IL45482A0 (en) 1974-11-29
ES429178A1 (en) 1976-09-01
DK135942C (en) 1977-12-19
DD115489A5 (en) 1975-10-05
GB1468079A (en) 1977-03-23
DK135942B (en) 1977-07-18
NL7410988A (en) 1975-02-20
CH603549A5 (en) 1978-08-31
BG24406A3 (en) 1978-02-10
DE2341876A1 (en) 1975-03-13

Similar Documents

Publication Publication Date Title
AU2004255934B2 (en) Isethionate salt of a selective CDK4 inhibitor
US5637611A (en) Medicaments
HU211576A9 (en) Indole derivatives
JP7473642B2 (en) Pyrrolopyrimidine Compounds as BTK Inhibitors and Their Use - Patent application
EP1904451A1 (en) Aryl-alkylamines and heteroaryl-alkylamines as protein kinase inhibitors
HU184727B (en) Process for preparing 3-/1-imidazolyl-alkyl/-indole derivatives
US20110060012A1 (en) 4-[3-(aryloxy)benzylidene]-3-methyl piperidine 5-membered aryl carboxamide compounds useful as faah inhibitors
JP2015505542A (en) Aza heterocyclic compounds
WO2009127943A1 (en) Ether benzylidene piperidine 5-membered aryl carboxamide compounds useful as faah inhibitors
JP2013534226A (en) Fused ring compounds for use as mineralocorticoid receptor antagonists
US20230140635A1 (en) 3-(2-(Aminoethyl)-Indol-4-ol Derivatives, Methods of Preparation Thereof, and the Use as 5-HT2 Receptor Modulators
US20110053949A1 (en) 4-[3-(aryloxy)benzylidene]-3-methyl piperidine aryl carboxamide compounds useful as faah inhibitors
US20110053950A1 (en) 4-benzylidene-3-methylpiperidine aryl carboxamide compounds useful as faah inhibitors
WO2019134573A1 (en) Method for preparing deuterated diphenylaminopyrimidine compound and crystal form thereof
NO742946L (en)
ZA200302636B (en) Arylpiperazine derivatives and their use as psychotropic agents.
SI9300542A (en) Benzofuran derivatives for medical use
WO2014037303A1 (en) Lpar - substituted cyanopyrazole compounds
TW544452B (en) Novel carboxy substituted cyclic carboxamide derivatives
TW414791B (en) Process and intermediates for preparing naphthyridonecarboxylic acid salts
NO761942L (en)
CN103649066B (en) 5-carbamyl-diamantane (obsolete)-2-yl amide derivatives, its pharmaceutically acceptable salt and preparation method thereof
WO1997045426A1 (en) Azetidine, pyrrolidine and piperidine derivatives as 5-ht1d receptor agonists
JP2008533192A (en) Substituted triazole derivatives as oxytocin antagonists
JPS6178767A (en) Bicyclic lactam, manufacture and blend containing same